title: [The effects of joint administration of 6% hydroxyethyl starch 130/0.4 and high-volume hemofiltration on patients with acute lung injury and acute kidney injury].
abstract: OBJECTIVE
  To evaluate the effects of administration of 6% hydroxyethyl starch (6% HES 130/0.4, voluven) in combination with high volume hemofiltration (HVHF) in patients with ALI and AKI.
  
  
  METHODS
  One hundred and eight patients with acute lung injury (ALI) and acute kidney injury (AKI) were enrolled from Department of Intensive Care Unit (ICU) of the provincial Hospital Affiliated to Shandong University between August 2006 and May 2011. The patients were randomly divided into two groups A (n = 68) and B (n = 40) to receive voluven (i.v., for volume resuscitation) and voluven+HVHF for 72 hours. The arterial blood lactate concentration (Lac), high sensitivity C-reactive protein (hs-CRP) serum concentration, pulmonary function index alveolar-arterial oxygen pressure difference [P(A-a)DO2] and oxygenation index (OI), as well as kidney function index serum cystatin C (Cyst C) and serum creatinine clearance rate (CCr) were measured at the time of admission and 72 hours after the treatment for statistical analysis.
  
  
  RESULTS
  In comparison with group A, group B had significantly (all P < 0.01) lower mean value in the level of arterial Lac (mmol/L: 1.7 ± 0.7 vs. 2.7 ± 1.5), serum hs-CRP (mg/L: 35.8 ± 18.8 vs. 99.5 ± 20.4), P(A-a)DO2 (mm Hg, 1 mm Hg=0.133 kPa: 115.5 ± 23.1 vs. 155.4 ± 27.4), Cyst C (mg/L: 2.06 ± 1.12 vs. 3.95 ± 2.06) and significantly higher (both P < 0.01) mean value of OI (mm Hg: 295.2 ± 38.8 vs. 239.5 ± 32.7) and CCr (ml/min: 108.71 ± 31.33 vs. 90.21 ± 30.35) 72 hours after treatment. The mortality rate of group B was significantly lower than group A [10.00%(4/40) vs. 29.41%(20/68), P < 0.05] 7 days after the admission.
  
  
  CONCLUSIONS
  6% HES 130/0.4 in combination with HVHF could improve the lung and kidney function of the patients with ALI and AKI, prevent the development of multiple organ dysfunction syndrome (MODS), therefore improve the survival rate of these patients.
authors.affiliation: Department of Intensive Care Unit, Shandong University, Jinan, Shandong, China.
authors.forename: Ji-cheng
authors.initials: JC
authors.lastname: Zhang
authors.forename: Hong-sheng
authors.initials: HS
authors.lastname: Ren
authors.forename: Jin-jiao
authors.initials: JJ
authors.lastname: Jiang
authors.forename: Min
authors.initials: M
authors.lastname: Ding
authors.forename: Mei
authors.initials: M
authors.lastname: Meng
authors.forename: Juan
authors.initials: J
authors.lastname: Zeng
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Chu
authors.forename: Wen-ying
authors.initials: WY
authors.lastname: Zhu
authors.forename: Guo-qiang
authors.initials: GQ
authors.lastname: Qi
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
authors.forename: Chun-ting
authors.initials: CT
authors.lastname: Wang
mesh_terms: D058186:Acute Kidney Injury / Q000628:therapy*; D055371:Acute Lung Injury / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000517:prevention & control; D011446:Prospective Studies; D055815:Young Adult
chemical_list: C485123:HES 130-0.4; D006895:Hydroxyethyl Starch Derivatives